Targeting CD123 in BPDCN: an emerging field

Targeting the p-D-C: easy as C-D-1-2-3?

(2021) Naveen Pemmaraju   BLOOD

Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm

(2021) Naveen Pemmaraju et al.   BLOOD

Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm

(2020) Matteo Piccini et al.   ANNALS OF HEMATOLOGY

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

(2020) Naval G. Daver et al.   BLOOD

New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm

(2020) Xiang Zhang et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Blastic plasmacytoid dendritic cell neoplasm

(2020) Kendra Sweet   CURRENT OPINION IN HEMATOLOGY

Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm

(2020) Sophia S Lee et al.   Expert Review of Anticancer Therapy

Rapidly Switchable Universal CAR-T cells for Treatment of CD123-positive Leukemia

(2020) Simon Loff et al.   Molecular Therapy-Oncolytics

Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm

(2020) Mohamed A. Kharfan-Dabaja et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm

(2020) Michael Haddadin et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm

(2020) Danielle Hammond et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm

(2020) Andrew A. Lane   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Recent advances in CAR-T cell engineering

(2020) Ruihao Huang et al.   Journal of Hematology & Oncology

Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data

(2020) Guillaume Beziat et al.   OncoTargets and Therapy

Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant

(2020) Seongseok Yun et al.   Blood Advances

Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia

(2020) Geoffrey L Uy et al.   BLOOD

Targeting CD123 in AML

(2020) Andrew A. Lane   Clinical Lymphoma Myeloma & Leukemia

Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review

(2020) Yazan Samhouri et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies

(2020) Hanadi El Achi et al.   Cancers

Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

(2020) Naveen Pemmaraju et al.   Blood Advances

Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients

(2020) Kamel Laribi et al.   Blood Advances

Tagraxofusp: First Global Approval

(2019) Yahiya Y. Syed   DRUGS

Blastic Plasmacytoid Dendritic Cell Neoplasm

(2019) Daniel Kerr et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm

(2019) Naveen Pemmaraju et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects

(2019) Maria Rosaria Sapienza et al.   Cancers

PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm

(2019) Phyu P. Aung et al.   Cancers

Dual Expression of TCF4 and CD123 is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm

(2019) Narittee Sukswai et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Multicenter Analysis of Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm Offers a Pre-Targeted Therapy Benchmark

(2019) Justin Taylor et al.   BLOOD

Blastic Plasmacytoid Dendritic Cell Neoplasm–Current Insights

(2019) Sangeetha Venugopal et al.   Clinical Lymphoma Myeloma & Leukemia

Promising results with tagraxofusp in BPDCN

(2019) Elizabeth Gourd   LANCET ONCOLOGY

FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

(2019) Emily Y. Jen et al.   CLINICAL CANCER RESEARCH

Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm

(2019) Minas P. Economides et al.   Expert Review of Clinical Pharmacology

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies

(2019) Testa et al.   Cancers

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance

(2019) Katsuhiro Togami et al.   JOURNAL OF CLINICAL INVESTIGATION

Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN)

(2019) Mansour Alfayez et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Antibody–Drug Conjugates with Indolinobenzodiazepine Dimer Payloads: DNA-Binding Mechanism of Indolinobenzodiazepine Dimer Catabolites in Target Cancer Cells

(2019) Rajeeva Singh et al.   MOLECULAR PHARMACEUTICS

Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

(2019) Minas P. Economides et al.   Current Hematologic Malignancy Reports

First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

(2018) Weili Sun et al.   Journal of Hematology & Oncology

8q24/ MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms

(2018) Prajwal C. Boddu et al.   LEUKEMIA RESEARCH

The advances in therapy of blastic plasmacytoid dendritic cell neoplasm

(2018) Daniel Kerr et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm

(2018) Guru Subramanian Guru Murthy et al.   LEUKEMIA RESEARCH

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target

(2018) Maria Rosaria Sapienza et al.   HAEMATOLOGICA

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond

(2017) Naveen Pemmaraju   Current Hematologic Malignancy Reports

Blastic Plasmacytoid Dendritic Cell Neoplasm: Update on Molecular Biology, Diagnosis, and Therapy

(2017) Wasif Riaz et al.   Cancer Control

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm

(2016) Michele Ceribelli et al.   CANCER CELL

A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm

(2016) Umberto Falcone et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

(2016) Joan Montero et al.   Cancer Discovery

Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy

(2016) Lourdes Martín-Martín et al.   Oncotarget

Treatment of blastic plasmacytoid dendritic cell neoplasm

(2016) J. M. Sullivan et al.   Hematology-American Society of Hematology Education Program

CAR T Cell Therapy: A Game Changer in Cancer Treatment

(2016) Hilde Almåsbak et al.   Journal of Immunology Research

Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm

(2015) T. Aoki et al.   BLOOD

Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform

(2015) M. Al-Hussaini et al.   BLOOD

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates

(2015) Gurunadh R. Chichili et al.   Science Translational Medicine

Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile

(2015) Lourdes Martín-Martín et al.   Oncotarget

Targeted diphtheria toxin to treat BPDCN

(2014) D. J. FitzGerald   BLOOD

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

(2014) A. E. Frankel et al.   BLOOD

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

(2014) F. Angelot-Delettre et al.   HAEMATOLOGICA

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

(2014) I Pizzitola et al.   LEUKEMIA

TET2mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow

(2013) Khaled Alayed et al.   AMERICAN JOURNAL OF HEMATOLOGY

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

(2013) A. Mardiros et al.   BLOOD

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor

(2013) Sarah Tettamanti et al.   BRITISH JOURNAL OF HAEMATOLOGY

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study

(2013) L. Pagano et al.   HAEMATOLOGICA

Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation

(2012) D. Roos-Weil et al.   BLOOD

Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC) in Elderly Patients: Results of a Treatment Algorithm Employing Allogeneic Stem Cell Transplantation with Moderately Reduced Conditioning Intensity

(2011) Sascha Dietrich et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion

(2010) Syd Johnson et al.   JOURNAL OF MOLECULAR BIOLOGY

Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia

(2009) Francine Garnache-Ottou et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia

(2008) Arthur Frankel et al.   LEUKEMIA & LYMPHOMA